Banks Rally While Biotech Soars Amid Crypto Selloff

Opening Recap

Market Pulse: Broad indexes barely moved as banking stocks pushed ahead while tech names slipped into negative territory, leaving sentiment slightly adrift.

Key Movers: Bank of America upgrades hit screens after a Q3 beat; Sarepta’s FDA approval lit up biotech corridors; Solana whales ratcheted up selling, testing crypto support.

Macro & Politics: Trump’s biosimilar-friendly plan and out-of-pocket caps for drug prices are gearing up to shake pharma giants as lobbying fires up.

What’s Next: Watch for fresh policy details on drug pricing and Solana’s support zone tests before the opening bell.

Market Commentary

What everyone’s missing is the lurking fallout in lodging from “Rollins Capital explores alternatives to Sotherly Hotels merger deal” (Thefly.com). Traders are fixated on bank upgrades and biotech wins, but a collapsed swap could trigger a waterfall of selling across lodging stocks—and that risk hasn’t even made headline pages yet.

Here’s a thought: the same herd chasing Sarepta after the FDA nod (“Sarepta confirms FDA approval of updated Elevidys prescribing information,” Thefly.com) is leaving crypto in the dust, where Solana faces heavy selling as whales flip bearish (Ambcrypto.com). It’s a classic chase for yield in biotech while digital assets get dumped—two sides of a market scrambling for returns.

Your move: rotate out of lodging speculation, hedge pharma ahead of policy noise, and lean into high-beta bank names riding those Q3 beats. That’s where the actionable edge lives.